Does Wegovy Make Your Heart Beat Faster?

Step 1, Recognise what's happening and why

Semaglutide acts on GLP-1 receptors found not just in the gut but also in cardiac tissue and the autonomic nervous system. The net result in some people is a modest rise in resting heart rate, typically in the range of one to four beats per minute on average across trial populations, though individual responses vary more widely. You might notice it as a fluttery feeling in your chest, a sense that your heart is working harder than usual, or simply that your pulse feels quicker when you check it.

The NHS semaglutide medicines page lists palpitations and a fast heartbeat among the uncommon side effects of semaglutide, meaning they affect somewhere between 1 in 100 and 1 in 10 people. They tend to appear in the first few weeks after a dose is started or increased, which is also the window when nausea and other gastrointestinal effects are most prominent. The two are unrelated mechanisms, but they often overlap in timing, which can make the early weeks feel busier than they later become.

If you are curious how this compares with the broader pattern of cardiovascular symptoms reported with semaglutide, the detailed picture is covered on our page about how Wegovy affects the heart more generally.

Step 2, Distinguish the common from the serious

Most reports of a faster heartbeat on Wegovy are mild and resolve without any change to treatment. The signal to watch for is persistence. If your heart rate remains elevated beyond the first month at a given dose, if it is accompanied by chest tightness, dizziness, breathlessness or fainting, or if it came on suddenly and feels severe, that is a different conversation entirely, speak to a doctor the same day, or call 999 if symptoms are acute.

There is a separate question worth asking: could the faster heartbeat have another cause? Dehydration is common in the early weeks of GLP-1 treatment, particularly if nausea has reduced your fluid intake. A dehydrated cardiovascular system compensates by increasing heart rate. So before concluding the medicine is the direct cause, your prescriber will want to know whether you are drinking enough, whether the sensation is positional (worse on standing), and whether you have any background heart conditions.

For a detailed look at the evidence on fast heart rate specifically, our page on Wegovy and fast heart rate walks through the trial data and clinical thresholds in full. And if you are wondering whether semaglutide as a class causes this effect, the pattern is explored on our page covering whether semaglutide makes your heart race.

Step 3 (Use the monitoring window wisely

The most useful thing you can do in the first four to eight weeks on Wegovy is track your resting heart rate) ideally first thing in the morning, before you get up, on the days you feel the flutter and the days you do not. A smartwatch or a simple finger oximeter will do. Share that pattern with your prescriber at your next review. A clinician who can see that your rate has moved from 62 to 68 bpm consistently is in a much stronger position to advise you than one told only that things feel a bit fast.

At nume, your prescriber reviews your case before every repeat order, not just at the start. If you have questions between orders, our aftercare team is available seven days a week. One of the questions our prescribers hear most often is whether an elevated pulse means treatment should stop; the answer depends on the full picture, not the number alone.

If the cost of maintaining monitored private treatment is on your mind, the Wegovy cost context page explains what responsible, clinically supervised private treatment typically involves and why the headline price is rarely the whole story.

Step 4, Know where Wegovy's heart story goes next

It is worth holding two things in mind at once. Yes, semaglutide can nudge your resting heart rate up modestly in the short term. At the same time, the SELECT cardiovascular outcomes trial demonstrated that adults with obesity and pre-existing cardiovascular disease experienced significantly fewer major cardiac events (heart attacks, strokes, cardiovascular deaths) on semaglutide 2.4mg compared with placebo. The MHRA has noted this dual picture in its public communications on GLP-1 medicines.

This does not mean a faster heartbeat should be dismissed. It means the clinical picture is genuinely nuanced, and a prescriber is the right person to weigh it for your specific circumstances. If you are currently on Wegovy or considering it and want to understand your cardiac history in that context, our page on Wegovy making your heart race covers patient-reported experience alongside the trial evidence. The broader overview of the treatment itself is on our Wegovy information page.

If you are ready to discuss your situation with a clinician, you can speak to our prescribers through a free consultation, reviewed the same day by a GPhC-registered Independent Prescriber, not automated software.